Criteria for Starting Evolocumab
Evolocumab should be initiated in adults with established atherosclerotic cardiovascular disease (ASCVD) who have LDL-C ≥100 mg/dL despite maximally tolerated statin therapy plus ezetimibe, in patients with familial hypercholesterolemia (FH) meeting specific thresholds, and in statin-intolerant patients at high cardiovascular risk. 1, 2
Primary Indications and LDL-C Thresholds
1. Established ASCVD (Highest Priority)
- Start evolocumab when LDL-C ≥100 mg/dL on maximally tolerated high-intensity statin plus ezetimibe 1, 3
- This includes patients with prior myocardial infarction, stroke, unstable angina, or coronary revascularization
- FDA-approved to reduce risk of CV death, MI, stroke, unstable angina requiring hospitalization, or coronary revascularization 2
- Evolocumab reduces cardiovascular events by 14-19% in general ASCVD populations, with potentially greater benefit (42-58% reduction) in patients with autoimmune/inflammatory diseases 4
Special consideration for diabetes: If patient has diabetes PLUS established ASCVD or chronic kidney disease or target organ damage, use the same threshold of LDL-C ≥100 mg/dL on maximally tolerated statin plus ezetimibe 3
2. Familial Hypercholesterolemia Without ASCVD
Heterozygous FH (HeFH):
- Start evolocumab when LDL-C ≥130 mg/dL on maximally tolerated statin plus ezetimibe 3
- Consider starting at LDL-C >140 mg/dL (>3.6 mmol/L) if additional risk factors present 5
- Additional risk factors that lower threshold include:
- Lipoprotein(a) >50 mg/dL
- Smoking or marked hypertension (≥160/100 mmHg)
- Age ≥40 years without treatment
- Premature ASCVD in first-degree relatives (<55 years males, <60 years females)
- Diabetes with target organ damage 5
Homozygous FH (HoFH):
- Initiate evolocumab as adjunct therapy regardless of specific LDL-C threshold 1, 2
- Requires some residual LDL receptor activity (>2%) for efficacy 5
- NOT recommended in patients with negative/negative LDLR mutations with <2% receptor activity 5
- Approved for adults and pediatric patients ≥10 years old 2
3. Statin Intolerance
- High cardiovascular risk: Start when LDL-C ≥100 mg/dL on any tolerated lipid-lowering therapy 3
- Very high cardiovascular risk: Start when LDL-C ≥130 mg/dL on any tolerated lipid-lowering therapy 3
Dosing Regimens
Per FDA labeling, evolocumab is administered subcutaneously 2:
- 140 mg every 2 weeks OR
- 420 mg once monthly (given as 3 consecutive 140-mg injections or via on-body infusor)
- For HoFH on apheresis: May use 420 mg every 2 weeks if more LDL-C reduction needed after 12 weeks 1
Key Clinical Considerations
Prerequisite therapy: The 2022 ACC guidelines emphasize that evolocumab should be added to maximally tolerated statin therapy, not used as monotherapy in most cases 1. The European guidelines similarly require maximally tolerated statin plus ezetimibe before considering PCSK9 inhibitors 5.
Expected LDL-C reduction: Evolocumab reduces LDL-C by approximately 55-60% from baseline 1, 6. Maximum LDL-C reduction occurs by 2 weeks with the 140-mg dose and 3 weeks with the 420-mg dose 2.
Safety in special populations:
- Chronic kidney disease: Evolocumab is effective and safe in CKD stages 3-4, with no significant deterioration in renal function 7
- Very low LDL-C levels: No increase in adverse events (including cognitive effects, hemorrhagic stroke, or liver enzyme elevation) observed with LDL-C <25 mg/dL 5
- Pediatric patients: Approved for ages ≥10 years with HeFH or HoFH 2
Common pitfall: Do not wait for cardiovascular events to occur in high-risk FH patients. The European guidelines specifically address FH patients without clinically diagnosed ASCVD who have substantially elevated LDL-C despite optimal therapy 5. These patients warrant PCSK9 inhibitor therapy based on LDL-C thresholds and additional risk factors, not just prior events.
Monitoring: Assess LDL-C response at 4-12 weeks after initiation 5. The drug reaches steady-state by 12 weeks of dosing 2.